“We really want to be a strong partner for our blood center customers in helping them deliver their important mission, which is to provide safe blood for patients.” – William ‘Obi’ M. Greenman President and CEO, Cerus. View the video ; Pathogen Reduced Cryoprecipitated Fibrinogen Complex Visit product website ; INTERCEPT® Blood System for Platelets and Plasma Visit US SiteVisit International Site ; At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe. See Mission and Values ; Annual Report Cerus’ Annual Meeting of Stockholders will be held online on Wednesday, June 5, 2024 at 8:00 a.m. Pacific Time. Read More Latest Press Releases 04/18/2024 Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024 READ MORE 03/26/2024 Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life READ MORE 03/19/2024 Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients READ MORE 03/05/2024 Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results READ MORE view all press releases